Key Highlights

  • 10x Genomics shares closed at $84.11 today, up 11.23%, touching a fresh 52-week high.
  • The rally follows continued momentum from raised full-year 2026 Revenue guidance of $610 million to $630 million.
  • The company's recently announced Proteintech Genomics Acquisition adds protein-detection capabilities to its single-cell and spatial platforms.
  • One analyst raised its price target to $68 from $20, reflecting a dramatic shift in sentiment toward the stock.

Multi-Day Rally Builds on Strong Earnings Momentum

10x Genomics (NASDAQ:TXG) shares closed sharply higher today, touching a fresh 52-week high and extending a multi-day rally built on renewed confidence in the company's growth trajectory following its August earnings beat. The rally has been reinforced by raised full-year 2026 revenue guidance of $610 million to $630 million, alongside continued strong early Demand for the company's newer Xenium and Visium platforms.

Proteintech Genomics Acquisition Adds New Capabilities

The recently announced Proteintech Genomics acquisition adds protein-detection capabilities to 10x Genomics' single-cell and spatial biology platforms, an expansion investors have welcomed as it broadens the company's product portfolio into adjacent segments of the life sciences tools market. Sentiment has also been buoyed by a dramatic analyst price-target increase, with one firm lifting its target to $68 from $20, reflecting a sharp reassessment of the stock's valuation.

A Leading Platform for Single-Cell and Spatial Biology

10x Genomics is a life science technology company headquartered in Pleasanton, California, that designs, manufactures and sells advanced instruments, consumables and software used to analyze biological systems at single-cell and spatial resolution. Its core Chromium platform enables single-cell gene expression, immune profiling and multiome analyses, while its Visium and Xenium platforms provide spatial gene expression and protein co-detection capabilities, serving academic, government, pharmaceutical and biotechnology customers globally.